Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Maravai LifeSciences Holdings, Inc. MRVI

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
1.88
Total sells
0.25
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 2 1 — — — — — — — — —
Sell — — — — — — — — 1 — — —
Insider Ownership
24.84%

Capital & Financial Ratios

Market Cap
1,890.00
Revenue
208.78
Net Income
(136.08)
Free Cash Flow
(35.84)
Net Debt
106.61
Current Ratio
4.05
Debt/Equity
0.50
P/E ratio
0.00
P/S ratio
4.94
P/B ratio
2.90
Past 5Y EPS Growth
(64.27%)
This Y EPS Growth
62.65%
Next Y EPS Growth
16.36%
Next 5Y EPS Growth
38.51%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
0.26%
total individual payouts
2025 ‡‡‡‡‡
2024 ‡‡‡‡‡
2023 ‡‡‡‡‡
2022 ‡‡‡‡
2021 ‡‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 574.96 322.40 216.89 70.09
Receivables 54.61 38.52 25.50 31.14
Inventory 51.40 50.08 40.50 41.23
Other — — — —
699.91 429.15 296.25 155.66
2023 2024 2025 Q'26
Payables 10.73 11.96 2.91 7.13
ST’ Debt 5.44 5.44 5.44 1.13
Other — — — —
87.47 56.97 44.92 38.42
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 65.84 51.44 — —
—
’25 46.85 47.40 41.63 49.87
185.74
’24 64.18 69.42 69.03 56.56
259.19
’23 79.03 68.91 66.87 74.14
288.95
’22 244.29 242.73 191.26 204.71
883.00
’21 148.21 217.78 204.81 228.44
799.24
’20 50.98 46.91 87.86 98.35
284.10
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 8.67 3.99 — —
—
’25 (9.39) (10.26) (15.15) (22.77)
(57.57)
’24 (8.47) 17.43 13.14 (14.64)
7.47
’23 85.07 19.19 14.17 7.79
126.22
’22 162.30 164.28 110.06 99.34
535.98
’21 38.33 165.94 105.56 58.74
368.57
’20 9.71 11.62 51.43 79.43
152.19
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 4.23 3.62 — —
—
’25 (13.89) (13.14) (18.81) (24.88)
(70.72)
’24 (14.13) 7.88 4.55 (20.79)
(22.49)
’23 77.21 (5.86) (1.66) (9.01)
60.67
’22 159.56 162.62 103.59 93.12
518.89
’21 35.54 161.41 104.23 53.09
354.27
’20 40.80 8.56 41.34 70.58
161.28
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.02) (0.08) — —
—
’25 (0.21) (0.27) (0.18) (0.24)
(0.90)
’24 (0.09) (0.05) (0.70) (0.18)
(1.05)
’23 0.00 (0.05) (0.05) (0.80)
(0.90)
’22 0.50 0.53 0.34 0.28
1.67
’21 0.24 0.44 0.23 0.42
1.56
’20 0.23 0.00 0.32 0.13
2.36

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1.9
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 12.16 4.52 4.28 1.67 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 41.87 16.90 11.56 6.21 — — —
High Price
— — — ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 610 650 570 435 — — —
Employees
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.45 0.44 0.45 0.43 — — —
Revenue/Emp
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 883.00 288.95 259.19 185.74 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 80.87% 48.52% 41.79% 18.30% — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 551.47 617.74 (261.48) (234.97) ‡‡‡‡‡ — —
EBT
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.45% 213.79% (100.89%) (126.50%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 490.66 (138.37) (259.62) (230.76) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.89 51.71 59.76 62.13 — — —
Depreciation
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.71 2.19 1.88 1.29 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 1.67 (0.90) (1.05) (0.90) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.07 0.96 0.05 (0.40) ‡‡‡‡ — —
Cash Flow/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.13) (0.50) (0.22) (0.09) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.94 0.46 (0.16) (0.49) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.88 5.99 4.19 2.58 ‡‡‡‡‡ — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 131.55 131.92 137.91 144.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.20 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.04 3.08 2.90 2.53 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.99 1.13 1.30 1.26 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.92 3.01 2.92 3.09 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.27 14.34 (34.07) (8.12) — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 535.98 126.22 7.47 (57.57) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.09) (65.55) (29.96) (13.15) ‡‡‡‡‡ — —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 518.89 60.67 (22.49) (70.72) ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 737.76 612.44 372.18 251.33 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 527.44 556.04 327.04 321.91 — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (104.70) (18.92) 4.64 105.02 — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 905.24 789.88 577.21 372.71 — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.48% (6.31%) (11.61%) (14.70%) ‡‡‡‡‡ — —
ROA
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.83% (2.57%) (25.31%) (28.16%) — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 30.36% (14.04%) (21.19%) (27.53%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Maravai LifeSciences Holdings (MRVI) exemplifies a pandemic boom-to-bust cycle, with revenues surging 99% to $284M in 2020 and peaking at $883M in 2022 amid mRNA vaccine demand, driving EBT margins to 66% and ROE above 50%. Profits ballooned to $491M net income, fueling a stock rally from $24-$32 to $26-$64. Yet post-2022, revenues cratered 67% to $289M in 2023 and 10% further to $259M in 2024, flipping to $260M losses, gross margins eroding to 42%, and shares tumbling to $3-$4 lows—questioning if it’s a value play or trap.

Insider optimism shines through: CEO and directors bought ~$1.88M in shares in late 2025, amid no sells. Analysts project revenue bottoming at $185M in 2025 before +10-7% rebounds to $218M by 2027, losses narrowing 55-33% to -$39M, and FCF turning positive at $13M. Multiples scream cheap at 2.9x PS, 1.3x PB, with average price targets implying 50% upside (high 70%), balanced against biotech volatility.

Current metrics track revenue shadows perfectly, with manageable debt and cash buffers offering runway for mRNA therapeutics pivot. Watch for Q1 2026 inflection—speculative rebound potential if non-COVID growth materializes.

Read full commentary →

Maravai LifeSciences Holdings, Inc. (MRVI) Latest News

News by impact score

Fine-tune

13 Aug

4 transcript www.fool.com, 8:16 PM
Maravai LifeSciences Holdings reported Q2 2026 financial results and outlook during its earnings call. Q2 earnings call delivers key financial metrics and guidance that can shift company trajectory and investor views.

7 Aug

3 transcript app.moby.co, 8:30 AM
Maravai LifeSciences Holdings, Inc. released its Q2 2026 earnings call summary covering quarterly financial results and business outlook. Quarterly earnings data can shift near-term investor views and valuation multiples but rarely redefine long-term strategy.

3 www.marketbeat.com, 1:04 AM
Maravai LifeSciences Holdings reported Q2 financial results and operational updates during its earnings call, covering revenue, margins, segment performance, and forward guidance. Q2 earnings data and guidance directly inform near-term financial expectations and investor positioning.

6 Aug

3 , 5:40 PM
Maravai LifeSciences Holdings reported a Q2 net loss while exceeding revenue estimates. Quarterly earnings outcomes affect near-term financial perception and stock movement.

3 , 4:01 PM
Maravai LifeSciences Holdings reported its second quarter 2026 financial results. Quarterly results update performance metrics without altering core operations or strategy.

20 Jul

3 , 4:02 PM
TriLink BioTechnologies obtains newly issued patent in China for CleanCap capping technology, strengthening global IP position. New China patent adds IP protection for core capping technology and supports competitive positioning.

16 Jun

3 , 8:30 AM
TriLink opened a GMP enzyme manufacturing facility enabling integrated IVT supply from R&D to commercial scale. New facility expands TriLink manufacturing capacity for scaled enzyme production.

3 Jun

3 Business Wire, 8:30 AM
Maravai LifeSciences Holdings refinances its credit agreement and extends maturity to 2032. Debt maturity extension to 2032 improves long-term financial stability for Maravai LifeSciences.

14 May

4 Simply Wall St., 9:29 PM
Maravai LifeSciences Holdings, Inc. (MRVI) narrative shifts with new targets and 2026 guidance, signaling evolving strategic outlook amid operational updates. New targets and 2026 guidance indicate major strategic moves likely to alter MRVI's trajectory and investor sentiment.

9 May

4 transcript www.fool.com, 4:35 PM
Maravai LifeSciences Holdings, Inc. (MRVI) released its Q1 2026 earnings call transcript, detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook likely to significantly influence MRVI's market trajectory and investor sentiment.

8 May

4 app.moby.co, 8:30 AM
Maravai LifeSciences Holdings, Inc. (MRVI) released its Q1 2026 earnings call summary, detailing financial results and forward guidance. Q1 2026 earnings call summary highlights financial performance and strategic outlook directly impacting MRVI's market trajectory and investor sentiment.

4 www.marketbeat.com, 5:09 AM
Maravai LifeSciences Holdings, Inc. (MRVI) released Q1 earnings call highlights detailing financial results, operational updates, and forward guidance. Q1 earnings highlights disclose key financial metrics and strategic outlook, poised to significantly sway investor sentiment and stock trajectory.

7 May

4 Zacks, 5:55 PM
Maravai LifeSciences Holdings, Inc. (MRVI) exceeded Q1 earnings and revenue estimates. Beating Q1 earnings and revenue estimates signals robust financial performance and enhances investor sentiment, potentially driving significant stock gains.

4 Business Wire, 4:01 PM
Maravai LifeSciences Holdings, Inc. (MRVI) reported first quarter 2026 financial results. Quarterly earnings announcements like Q1 2026 results directly shape investor sentiment and can significantly alter market performance trajectory.

6 May

3 Zacks, 12:00 PM
Analysts upgraded Maravai LifeSciences Holdings, Inc. (MRVI) rating to Buy, highlighting positive outlook on its performance and growth potential. Analyst upgrade to Buy likely boosts investor sentiment and short-term stock performance without fundamentally altering long-term trajectory.

13 Apr

3 Simply Wall St., 3:08 AM
Maravai LifeSciences (MRVI) Q4 results highlight weakened demand in nucleic acid production and genomics, leading to lowered 2024 guidance, revenue decline, and a cautious valuation outlook despite cost-cutting measures. Q4 results and lowered guidance moderately affect MRVI's financial performance and investor sentiment without fundamentally altering long-term trajectory.

29 Mar

3 Simply Wall St., 10:06 PM
Analysts are reworking fair value targets for Maravai LifeSciences (MRVI), signaling a shift in the company's investment narrative. Analyst revisions to fair value targets can moderately influence investor sentiment and MRVI's market performance.

26 Feb

4 app.moby.co, 8:30 AM
Maravai LifeSciences Holdings, Inc. released Q4 2025 earnings call summary detailing financial results, strategic updates, and outlook for the life sciences firm. Q4 earnings call summaries disclose financial performance and guidance that significantly influence investor sentiment and stock trajectory.

4 www.marketbeat.com, 2:11 AM
Maravai LifeSciences Holdings, Inc. (MRVI) released Q4 earnings call highlights, covering financial results, operational updates, strategic initiatives, and forward guidance. Q4 earnings call highlights disclose key financial metrics, growth strategies, and outlook that significantly shape investor expectations and stock performance.

25 Feb

4 Business Wire, 4:01 PM
Maravai LifeSciences Holdings, Inc. (MRVI) reported fourth quarter and full-year 2025 financial results. Quarterly and annual earnings reports directly shape investor sentiment, stock valuation, and future performance expectations for MRVI.

3 Zacks, 7:25 PM
Maravai LifeSciences Holdings, Inc. (MRVI) reported a Q4 loss but beat revenue estimates. Q4 revenue beat despite loss moderately influences financial performance and investor sentiment.

6 Feb

4 www.fool.com, 5:38 AM
Maravai LifeSciences Holdings, Inc. (MRVI) has seen its stock price surge nearly 100%, attracting significant investor interest. A notable fund recently capitalized on this momentum, executing a $10 million exit to lock in gains. The surge in stock value reflects positive market sentiment and potential growth prospects for the biopharma company. The significant stock surge and the fund's exit indicate strong market interest and potential shifts in investor sentiment that could impact future performance.

6 Jan

3 Simply Wall St., 6:40 AM
Maravai LifeSciences Holdings, Inc. (MRVI) is highlighted as one of three undervalued small-cap stocks experiencing insider buying. The article emphasizes the potential for growth in MRVI, particularly in the context of its role in the life sciences sector and ongoing demand for its products. Insider buying is presented as a positive signal regarding the company's future prospects, suggesting confidence from those within the organization. Insider buying indicates confidence in the company's future, but the overall impact on performance is expected to be limited.

16 Dec

3 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 9:07 AM
Analysts are reassessing Maravai LifeSciences Holdings, Inc. following a target price cut and a significant drop in share price. The company's recent performance has raised concerns, leading to a shift in sentiment among investors. Despite these challenges, some analysts believe that the stock may be undervalued and could present a buying opportunity as the market adjusts to the new price targets. The target price cut and share price decline indicate a moderate influence on investor sentiment and potential financial performance.

2 Dec

3 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 3:15 AM
Maravai LifeSciences Holdings, Inc. is undergoing a management shakeup, prompting analysts to reassess the company's future. While there are opportunities for growth, particularly in expanding its product offerings and market reach, risks remain due to potential disruptions and the need for strategic realignment. Investors are advised to weigh these factors as the company navigates this transitional phase. The management changes could moderately influence Maravai's operational effectiveness and market positioning.

17 Nov

3 Simply Wall St., 12:08 PM
Analysts are adjusting their views on Maravai LifeSciences Holdings, Inc. (MRVI) as the company's narrative evolves, reflecting changes in market dynamics and performance expectations. Recent developments indicate a shift in sentiment, with analysts reassessing growth prospects and potential challenges ahead. The company's strategic initiatives and market positioning are under scrutiny, influencing investor outlook and stock performance. Analyst sentiment shifts indicate a moderate influence on Maravai's financial performance and competitive positioning.

15 Nov

3 Simply Wall St., 7:32 AM
CEO and Director of Maravai LifeSciences Holdings, Inc. purchased an additional 13% of the company's stock, signaling confidence in the firm's future prospects. This acquisition adds to the CEO's existing holdings and reflects a positive outlook on the company's performance and market position. Insider buying can indicate confidence in the company's future, potentially influencing market sentiment and stock performance.

7 Nov

3 transcript GuruFocus.com, 12:12 AM
Maravai LifeSciences Holdings, Inc. (MRVI) reported its Q3 2025 earnings, highlighting a strategic focus on expanding its product offerings and enhancing operational efficiencies. The company emphasized its commitment to innovation and addressing market demands, while also navigating challenges in the competitive landscape. Financial results showed a mixed performance, with certain segments outperforming expectations, contributing to a cautious yet optimistic outlook for future growth. The earnings call revealed key insights into product innovation and operational strategies that may moderately influence financial performance.

6 Nov

4 , 4:01 PM
Maravai LifeSciences Holdings, Inc. (MRVI) reported its financial results for the third quarter of 2025, highlighting significant revenue growth driven by increased demand for its products and services. The company noted strong performance in its core segments, with a notable rise in sales of its nucleic acid products. Additionally, Maravai provided an optimistic outlook for the remainder of the fiscal year, citing ongoing investments in research and development as key to sustaining growth. The results reflect the company's strategic focus on expanding its market presence and enhancing operational efficiencies. Significant revenue growth and a positive outlook indicate major strategic moves that could alter the company's trajectory.

3 Zacks, 6:15 PM
Maravai LifeSciences Holdings, Inc. (MRVI) reported a loss in Q3, falling short of revenue estimates. The company's financial performance has raised concerns among investors, as it struggles to meet market expectations amid a challenging economic environment. The missed revenue estimates and reported loss may moderately influence investor sentiment and financial performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us